NAFTIN® Cream, 1% contains the synthetic, broad-spectrum, antifungal agent naftifine hydrochloride.
NAFTIN® Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris and tinea corporis caused by the organisms
Tricophyton rubrum, Tricophyton mentagrophytes,
Published Studies Related to Naftin (Naftifine)
A randomized, double-blind, vehicle-controlled efficacy and safety study of
naftifine 2% cream in the treatment of tinea pedis. 
treatment for four weeks and vehicle were also evaluated as a positive control... CONCLUSION: Topical NAFT-2 for two weeks is safe and provides significantly
Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. [1993.10]
In a multicentre, double-blind, randomized, parallel group study in general practice, 269 patients with clinically diagnosed fungal infection of the skin were treated with either naftifine (Exoderil) or 1% clotrimazole plus 1% hydrocortisone (CHC; Canesten HC) applied twice daily for 4 weeks... This study suggests that there is no clinical advantage in treating patients with clinically diagnosed fungal infection of the skin with an antimycotic/corticosteroid combination as opposed to naftifine alone.
Once-daily naftifine cream 1% in the treatment of tinea cruris and tinea corporis. [1990.07]
Seventy patients with tinea cruris or tinea corporis were treated with naftifine cream 1% or vehicle once daily for 4 weeks in this double-blind, randomized study. After two weeks, the patients using naftifine had a significantly higher mycologic cure rate than the vehicle-treated patients (79% vs...
In vitro and in vivo cutaneous penetration and antifungal activity of naftifine. [1989.10]
The topical antifungal agent naftifine has shown considerable potency against a broad spectrum of dermatophytes. In this study, an in vitro penetration test in human cadaver skin and an in vivo tape-stripping test were used to evaluate the penetration and antifungal activity of naftifine gel 1 percent and naftifine cream 1 percent compared with other antifungal agents...
A double-blind clinical trial of fenticonazole (2%) spray versus naftifine (1%) spray in patients with cutaneous mycoses. 
A multi-centre, double-blind trial was carried out in 100 patients with cutaneous mycotic infections, confirmed by direct microscopy and/or culture, to compare the efficacy and tolerability of spray formulations of 2% fenticonazole and 1% naftifine. On entry, patients were allocated at random to receive once daily topical applications of one or other drug over a period of 2 to 4 weeks, treatment being stopped when patients had recovered or substantially improved...
Clinical Trials Related to Naftin (Naftifine)
Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis [Recruiting]
This study is being done to see how the body is affected when a study drug is applied to
both feet if the subject has athlete's foot or to both feet and the groin area if the
subject have both athlete's foot and jock itch. Safety of the drug and how well the drug
works will also be measured.
Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis [Recruiting]
This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group
Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in
the treatment of tinea pedis.
Topical Gel Anti-Fungal Agent for Tinea Unguium [Completed]
The purpose of this study is to compare, in a controlled fashion, the response to two
anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations
in the treatment of subjects with distal subungual tinea unguium of the toenails
The formulation used as the vehicle for the active agents has been shown in earlier studies
to facilitate the penetration of the active agent through fungally-infected nails. This
study will examine dose-response and agent differences in terms of efficacy and safety.
Once the subject has qualified for the study, he/she will be randomly assigned to one of five
study groups, dispensed appropriate study medication and instructed to apply one drop to the
great toe designated for study.